Flumatinib, venetoclax combined with azacitidine for treatment of Ph + mixed-phenotype acute leukemia: report of 2 cases and review of literature
10.3760/cma.j.cn115356-20241121-00177
- VernacularTitle:氟马替尼、维奈克拉、阿扎胞苷联合治疗Ph +混合表型急性白血病2例并文献复习
- Author:
Siyu LIU
1
;
Yimin HU
;
Junfan LI
;
Hong LIU
;
Lihua WU
;
Xiyan WANG
;
Runxia GU
;
Ying WANG
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所） 血液与健康全国重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室，天津 300020
- Keywords:
Leukemia, biphenotypic, acute;
Philadelphia chromosome;
Flumatinib;
Venetoclax;
Azacitidine;
Drug therapy, combination
- From:
Journal of Leukemia & Lymphoma
2025;34(4):213-217
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and safety of the triplet regimen of flumatinib, venetoclax (VEN) and azacitidine (AZA) for Philadelphia chromosome-positive (Ph +) mixed-phenotype acute leukemia (MPAL). Methods:The clinical data of 2 Ph + MPAL patients treated with triplet regimen of flumatinib, VEN and AZA who were admitted to the Institute of Hematology & Blood Diseases Hospital of Chinese Academy of Medical Sciences & Peking Union Medical College in February and March 2023 were retrospectively analyzed, and the relevant literature was reviewed. Results:Patient 1 was a 56-year-old female, and patient 2 was a 59-year-old male. Both patients were diagnosed with Ph + B cell/myeloid (B/My) MPAL. After the first course of induction chemotherapy with the triplet regimen, patient 1 achieved hematological complete remission (HCR), complete cytogenetic remission (CCyR) and major molecular response (MMR), and patient 2 achieved HCR and CCyR. During the entire treatment process, the adverse reactions of two patients were mainly fever and ≥ grade 3 hematological adverse reactions, which were relieved after the use of antibiotics and intermittent infusion of blood products. When the patient achieved HCR and received consolidation treatment with the same regimen, the adverse reactions were mild. Conclusions:The triplet regimen of flumatinib, VEN and AZA is safe and effective for the treatment of Ph + MPAL, and is a new induction therapy option for such patients.
